Investor Profile: BGF — Thesis, Cheque Size & How to Apply

BGF funding has become one of the best-known routes for British and Irish scale-ups. Set up in 2011 to address the UK's SME funding gap, BGF is the country's most active investor in growth-stage companies, with £3.5bn in assets under management and more than £5bn deployed across 650+ businesses over 15 years. Its offer to founders is simple: patient, minority capital that never takes control — plus support built for scaling companies.

Thesis & focus

BGF exists to fill the equity gap for SMEs that are too big for seed capital but too independent-minded for traditional private-equity buyouts. It invests minority, non-controlling stakes with a patient outlook — no fixed exit deadlines — and keeps follow-on funding available for new growth opportunities. Backed by Barclays, HSBC, Lloyds and NatWest as main shareholders, it operates through 15 offices across the UK and Ireland and invests across every sector, from deep tech to consumer brands.

Sectors & stages

BGF runs two tracks. Its Growth Stage team backs established SMEs across all sectors — technology, healthcare, consumer, industrials. Its Early Stage team focuses on late seed to Series B startups innovating in life sciences or deep tech, typically IP-protected, research-led companies and university spinouts. Recent activity spans medtech, AI, fintech and consumer brands, and in 2026 BGF was named the most active investor in the UK's 245 fastest-growing private equity-backed companies.

Fund size & cheque size

BGF manages £3.5bn and has committed to invest a further £3bn over the next five years. Growth Stage cheques run £3m–£30m as an initial investment, for businesses typically doing £1m–£10m in profit — or £3m+ in ARR for tech. Early Stage cheques run £3m–£10m from BGF as part of £5m–£30m total rounds. Since 2016, its exits have delivered a 22.6% gross IRR and a 2x money multiple — the performance record behind the patient-capital claim.

BGF funding wins: notable portfolio

BGF currently backs around 360 businesses and has completed more than 280 exits. Standout results include the 2025 exit of OrganOx at a $1.5bn valuation — one of the largest medtech exits in UK history — alongside the exit of Voicescape to Elevare after 2.5x ARR growth, the exit of luxury fashion brand Strathberry after five-fold revenue growth, and a €13m minority investment in Ireland's Redfaire. Across its history, portfolio companies have generated £8.2bn in revenue growth and created more than 35,000 jobs.

Partners & team

BGF is led by CEO Andy Gregory and chief investment officer Ben Barker. Beyond capital, BGF runs a structured value-creation programme: talent mapping and search, access to new customers, board-level support, structured learning programmes, exit planning, and founder and C-suite communities — the 'value beyond investment' layer many founders cite as the real reason to take BGF money.

How to apply for funding

BGF invites founders to complete its online 'Introduce yourself' form on bgf.co.uk. The form asks for your company registration number, investment stage, employee count and EBITDA, how much you are looking to raise and why you are seeking funding. The investment team reviews every submission and follows up where the fit looks right. A typical deal process then runs through an initial meeting, information sharing, heads of terms, third-party due diligence and deal completion.